drug · small molecule
lorecivivint
pre_registrationupdated 3mo agoby Biosplice Therapeutics Inc🔗 ChEMBL
community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.
targets
Dual specificity protein kinase CLK2Dual specificity tyrosine-phosphorylation-regulated kinase 1A
all catalysts(0)
nothing on the calendar yet
Trials studying lorecivivint
- phase33-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis
- phase3A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee
- phase2MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee Osteoarthritis
- phase3Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis
- phase3Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)
- phase3A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that